Journal of Obesity & Metabolic Syndrome, 30(1), 2031
2023 NEJM) in 17,604 cardiovascular patients showed similar constipation rates, confirming the pattern across populations
Ultimately, the goal of supplementation is to provide your body with what it needs in a form it can actually use
Major trends: Dual-label drugs (diabetes and obesity) driving cross-prescription and expanding the addressable patient population, High patient demand for weight loss benefits, often leading to off-label prescribing and direct-to-consumer marketing, Payer scrutiny on cost-effectiveness of weight management in diabetes, with prior authorization requirements and step therapy, Development of next-generation GLP-1 drugs with enhanced weight loss efficacy (e.g., tirzepatide, retatrutide), and Integration of weight management programs with GLP-1 therapy, including digital coaching and adherence support